Windlas Biotech Ltd
Pharmaceuticals & Biotechnology | Small Cap
Windlas Biotech demonstrates a mixed financial performance. The company shows strong solvency, growth, coverage, and profitability. It maintains a very low level of debt and robust growth in revenue, operating profit, and earnings per share, alongside excellent interest and dividend coverage. Profitability metrics such as gross profit margin, ROCE, ROE, ROA, and operating and net margins are also very strong. However, there are concerns regarding liquidity and efficiency. The company's liquidity ratios suggest challenges in meeting short-term obligations, while efficiency ratios indicate potential issues with asset utilization, particularly in fixed assets and capital turnover. Financial ratios also present some weaknesses. Overall, Windlas Biotech exhibits solid financial health driven by growth and profitability, but needs to address areas related to liquidity and efficiency to ensure long-term stability and performance.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio5.00
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio5.86
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
Windlas Biotech demonstrates a mixed financial performance. The company shows strong solvency, growth, coverage, and profitability. It maintains a very low level of debt and robust growth in revenue, operating profit, and earnings per share, alongside excellent interest and dividend coverage. Profitability metrics such as gross profit margin, ROCE, ROE, ROA, and operating and net margins are also very strong. However, there are concerns regarding liquidity and efficiency. The company's liquidity ratios suggest challenges in meeting short-term obligations, while efficiency ratios indicate potential issues with asset utilization, particularly in fixed assets and capital turnover. Financial ratios also present some weaknesses. Overall, Windlas Biotech exhibits solid financial health driven by growth and profitability, but needs to address areas related to liquidity and efficiency to ensure long-term stability and performance.
Overall Valuation Score
P/E RATIO (TTM)
25.35
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
25.92
P/B RATIO
2.97
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.83
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.49
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹816 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company exhibits excellent growth across all key metrics. Strong revenue growth, operating profit growth, EPS growth, asset growth, and net income growth reflect robust business expansion and effective management strategies. This indicates a positive trajectory and strong potential for future performance. The company is effectively scaling its operations and profitability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.88 | 10.09 | 23 | 20.44 | 18.95 |
| Operating Profit Growth Rate | -3.64 | 13.21 | 30 | 20.51 | 11.7 |
| Earnings Per Share (EPS) Growth | 126.5 | 13.34 | 39.4 | 3.54 | 8.78 |
| Asset Growth Rate | 65.88 | 7.74 | 18.34 | 21.41 | 19.34 |
| Net Income Growth Rate | 680 | 10.26 | 34.88 | 5.17 | 8.2 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial metrics present a mixed view. While the dividend per share is well-managed, the adjusted EPS, cash EPS, and book value per share suggest areas needing attention. The high capital expenditures indicate significant investments, but their returns are not yet fully reflected in the earnings. The company should focus on optimizing its investments and improving earnings quality. The long-term sustainability of these investments needs careful evaluation.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 17.73 | 21 | 29 | 30.5 | 30 |
| Cash Earnings Per Share (Cash EPS) | 23.18 | 27.5 | 35.5 | 44.5 | 44.09 |
| Book Value Per Share | 179.55 | 201 | 225 | 252.5 | 264.09 |
| Dividend Per Share (DPS) | 3.54 | 4.01 | 5.59 | 5.79 | 6.3 |
| Capital Expenditures (CapEx) | 15 | 70 | 38 | 52 | 68 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability across all key metrics. Strong gross profit margin, ROCE, ROE, ROA, operating margin, and net margin reflect effective cost management and operational efficiency. This indicates a highly profitable and well-managed business. The company is generating substantial returns on its investments and assets.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 8.8 | 9.36 | 10.3 | 8.68 | 8.19 |
| Return on Capital Employed (ROCE) | 15 | 14 | 18 | 17 | 16 |
| Return on Equity (ROE) | 9.87 | 10.7 | 12.89 | 12.08 | 11.36 |
| Return on Assets (ROA) | 10.79 | 11.34 | 12.46 | 12.37 | 11.58 |
| Operating Margin | 11.37 | 11.7 | 12.36 | 12.37 | 11.62 |
| Net Margin | 8.37 | 8.38 | 9.19 | 8.03 | 7.3 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency metrics reveal a mixed performance. While the inventory turnover and days sales in inventory are reasonably managed, the fixed asset turnover, receivables turnover, receivable days, and capital turnover ratios indicate potential areas of concern. The company could improve asset utilization and management of receivables to enhance overall efficiency. There is a need to optimize the use of fixed assets and improve the collection of receivables to boost operational effectiveness.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 5.12 | 4.71 | 3.53 | 3.41 | 4.17 |
| Inventory Turnover Ratio | 8.5 | 6.94 | 8.26 | 9.71 | 11.61 |
| Receivables Turnover Ratio | 4.91 | 4.5 | 4.99 | 5.02 | 4.59 |
| Days Sales in Inventory Ratio | 42.94 | 52.59 | 44.19 | 37.59 | 31.44 |
| Receivable Days | 74.34 | 81.11 | 73.15 | 72.71 | 79.52 |
| Capital Turnover Ratio | 1.18 | 1.26 | 1.39 | 1.49 | 1.54 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates excellent coverage ratios. The high-interest coverage ratio indicates a strong ability to meet its interest obligations. The equity dividend coverage ratio shows a strong ability to cover dividend payments. This reflects a solid financial cushion for both debt and equity holders. The company is well-positioned to manage its financial obligations effectively.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 47 | 58 | 78 | 20.75 | 18.4 |
| Equity Dividend Coverage Ratio | 5 | 5 | 5 | 5 | 5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits excellent solvency. The very low debt ratio and debt-to-equity ratio, combined with a high equity ratio and debt to asset ratio, indicate a strong financial position with minimal reliance on debt. This provides financial stability and reduces the risk of financial distress. This signifies a very conservative approach to leverage, which can support long-term sustainability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt to Equity Ratio | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| Equity Ratio | 1 | 0.99 | 0.99 | 0.99 | 0.99 |
| Debt To Asset Ratio | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position reflects a mixed outlook. While the quick ratio suggests a reasonable ability to meet short-term obligations, the lower cash and operating cash flow ratios indicate potential challenges in immediate cash availability and operational cash generation. Though the current ratio is at an average level, the company might face difficulties in efficiently managing its current assets to cover its current liabilities, which may affect day to day operations.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.45 | 2.46 | 1.56 | 1.24 | 1.14 |
| Quick Ratio | 2.83 | 1.84 | 1.2 | 0.91 | 0.95 |
| Cash Ratio | 1.2 | 0.21 | 0.18 | 0.06 | 0.01 |
| Operating Cash Flow Ratio | 0.1 | 0.5 | 0.63 | 0.27 | 0.33 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 7 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 8 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 9 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 17 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 18 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 19 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
Windlas Biotech demonstrates mixed management effectiveness. Revenue expansion is robust, with consistent sales growth. However, profit growth is volatile and slowing down, and there's a noticeable increase in borrowings in the most recent year. Overall, the company demonstrates strengths in revenue generation and operational efficiency, but profit volatility and increased debt raise concerns about financial management.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (2025) | 20.43% | Strong ability to expand its revenue base. |
| Promoter Holding (Mar 2025) | 62.34% | Promoters' confidence in the company's future performance. | |
| CONS | Profit Growth (2025) | 5.17% | Inconsistent and shows signs of slowing down. |
| Borrowings (2025) | ₹ 32.57 Cr | Increase in debt could elevate financial risk and interest expenses. |
Financial Performance & Growth
Windlas Biotech demonstrates promising revenue growth alongside concerns regarding profit sustainability. The company has shown strong sales growth, but profit growth is volatile.
PROS: Sales Growth Windlas Biotech exhibits consistent sales growth over the years, indicating a strong ability to expand its revenue base.
| Metric | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|
| Sales Growth (%) | 1.43 | 14.47 | 22.97 | 20.43 |
| Compounded Sales Growth (5 Years) | - | 18% | - | - |
| Compounded Sales Growth (3 Years) | - | 18% | - | - |
| TTM Sales Growth | - | - | - | 20% |
CONS: Profit Growth While sales growth is strong, profit growth is inconsistent and shows signs of slowing down. This inconsistency may indicate challenges in maintaining profitability as the company scales its operations.
| Metric | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|
| Profit Growth (%) | 162.56 | 8.29 | 34.88 | 5.17 |
| Compounded Profit Growth (5 Years) | - | 30% | - | - |
| Compounded Profit Growth (3 Years) | - | 17% | - | - |
| TTM Profit Growth | - | - | - | 5% |
Capital Efficiency & Returns
Windlas Biotech maintains adequate capital efficiency and returns, suggesting effective use of shareholder funds and capital.
PROS: Return on Capital Employed (ROCE) ROCE indicates how effectively the company is using its capital to generate profits. Windlas Biotech's ROCE has remained relatively stable.
| Metric | 2019-2021 | 2022-2024 | 2025 |
|---|---|---|---|
| ROCE (%) | 15.33 | 15.67 | 17 |
PROS: Return on Equity (ROE) ROE measures the return generated on shareholders' equity. Windlas Biotech's ROE has been stable.
| Metric | 2019-2021 | 2022-2024 |
|---|---|---|
| ROE (%) | 16.24 | 16.87 |
Financial Health & Prudence
Windlas Biotech shows mixed signals in its financial health. Debt management is a concern due to increasing short-term borrowings, but consistent dividend payouts indicate a commitment to shareholder returns.
CONS: Debt Management The company's borrowings have increased in the most recent year, primarily due to a rise in short-term borrowings. This increase in debt could elevate financial risk and interest expenses.
| Metric | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|
| Borrowings (₹ Cr) | 39.57 | 4.48 | 4.11 | 32.57 |
PROS: Dividend Payout Windlas Biotech has been consistently sharing profits with its shareholders through dividend payouts. A consistent dividend payout ratio reflects a stable financial policy and confidence in future earnings.
| Metric | 2018-2021 | 2022-2025 | |---|---| | Dividend Payout (%) | 0 | 20 |
Shareholding & Ownership Structure
Windlas Biotech benefits from a strong promoter holding, indicating aligned interests and confidence in the company's prospects.
PROS: Promoter Holding A high promoter holding demonstrates the promoters' confidence in the company's future performance. Windlas Biotech has maintained a consistently high promoter holding.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoter Holding (%) | 59.95 | 62.37 | 62.82 | 62.34 |
Windlas Biotech faces moderate risk due to segment performance volatility and increasing debt. Sales growth is robust, but profit growth is inconsistent. The company's reliance on specific segments and increased borrowings raise concerns. While promoter holding remains strong, the overall risk profile is considered moderate, requiring vigilance in managing financial leverage and operational stability.
Segment performance volatility
The segment performance of Windlas Biotech exhibits some volatility, which could impact overall financial stability. Monitoring segment contributions and performance metrics is important to mitigate risks associated with fluctuating segment results.
Foreign exchange or interest rate exposure
Windlas Biotech's exposure to foreign exchange or interest rate fluctuations can pose a risk to its financial performance. It is important to manage these exposures through hedging strategies or other risk mitigation techniques to ensure stability in earnings and cash flows.
Regulatory compliance cost trends
The cost of regulatory compliance for Windlas Biotech can impact its profitability and competitive positioning. Monitoring trends in regulatory costs and implementing efficient compliance processes are important to mitigate this risk.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10815.47Bullish
- SMA 20815.21Bullish
- SMA 50816.61Bearish
- EMA 10816.34Bearish
- EMA 20816.07Bearish
- EMA 50816.44Bearish
- DEMA 10817.27Bearish
- DEMA 20815.75Bullish
- DEMA 50816.97Bearish
- TEMA 10818.14Bearish
- TEMA 20816.41Bearish
- TEMA 50814.98Bullish
- MACD-0.03Bullish
- ADX23.50Weak Trend
- IndicatorValueSignal
- RSI49.69Neutral
- CCI-17.35Neutral
- ROC 91.25Bullish
- ROC 140.62Bullish
- ROC 25N/ABearish
- Stoch K50.22Neutral
- Stoch D56.13Neutral
- IndicatorValueSignal
- BB Upper826.05Neutral
- BB Middle815.21Neutral
- BB Lower804.37Neutral
- ATR9.13Low Volatility
- IndicatorValueSignal
- MFI46.83Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10814.26Bullish
- SMA 20816.95Bearish
- SMA 50816.84Bearish
- EMA 10815.92Bullish
- EMA 20816.40Bearish
- EMA 50815.43Bullish
- DEMA 10815.70Bullish
- DEMA 20815.73Bullish
- DEMA 50818.33Bearish
- TEMA 10816.49Bearish
- TEMA 20814.67Bullish
- TEMA 50818.92Bearish
- MACD-0.50Bullish
- ADX20.03Weak Trend
- IndicatorValueSignal
- RSI49.59Neutral
- CCI-60.23Neutral
- ROC 9-0.81Bearish
- ROC 14-1.04Bearish
- ROC 250.87Bullish
- Stoch K40.61Neutral
- Stoch D42.28Neutral
- IndicatorValueSignal
- BB Upper827.71Neutral
- BB Middle816.95Neutral
- BB Lower806.19Neutral
- ATR12.85Low Volatility
- IndicatorValueSignal
- MFI40.43Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10816.85Bearish
- SMA 20817.67Bearish
- SMA 50805.50Bullish
- EMA 10815.97Bullish
- EMA 20815.59Bullish
- EMA 50812.08Bullish
- DEMA 10815.24Bullish
- DEMA 20817.78Bearish
- DEMA 50815.03Bullish
- TEMA 10814.18Bullish
- TEMA 20816.69Bearish
- TEMA 50N/AN/A
- MACD1.21Bearish
- ADX26.15Strong Trend
- IndicatorValueSignal
- RSI50.63Neutral
- CCI1.09Neutral
- ROC 9-0.55Bearish
- ROC 14-0.23Bearish
- ROC 251.08Bullish
- Stoch K33.68Neutral
- Stoch D23.20Neutral
- IndicatorValueSignal
- BB Upper833.81Neutral
- BB Middle817.67Neutral
- BB Lower801.52Neutral
- ATR20.03Low Volatility
- IndicatorValueSignal
- MFI72.71Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10819.39Bearish
- SMA 20815.07Bullish
- SMA 50823.90Bearish
- SMA 100800.86Bullish
- SMA 200834.96Bearish
- EMA 10816.70Bearish
- EMA 20815.15Bullish
- EMA 50811.34Bullish
- EMA 100812.24Bullish
- EMA 200830.42Bearish
- DEMA 10817.90Bearish
- DEMA 20817.40Bearish
- DEMA 50817.01Bearish
- DEMA 100798.54Bullish
- DEMA 200802.61Bullish
- TEMA 10816.24Bearish
- TEMA 20818.35Bearish
- TEMA 50821.92Bearish
- TEMA 100815.26Bullish
- TEMA 200766.46Bullish
- MACD1.89Bullish
- ADX16.18Weak Trend
- IndicatorValueSignal
- RSI50.58Neutral
- CCI12.23Neutral
- ROC 140.36Bullish
- ROC 257.04Bullish
- Stoch K37.09Neutral
- Stoch D43.70Neutral
- IndicatorValueSignal
- BB Upper838.94Neutral
- BB Middle815.07Neutral
- BB Lower791.19Neutral
- ATR28.94Low Volatility
- IndicatorValueSignal
- MFI45.77Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20799.61Bullish
- SMA 50854.65Bearish
- EMA 20811.63Bullish
- EMA 50834.17Bearish
- DEMA 20801.69Bullish
- DEMA 50818.58Bullish
- TEMA 20819.21Bullish
- TEMA 50763.82Bullish
- MACD-4.58Bullish
- ADX12.51Weak Trend
- IndicatorValueSignal
- RSI49.54Neutral
- CCI-33.02Neutral
- ROC 1410.89Bullish
- ROC 255.99Bullish
- Stoch K62.79Neutral
- Stoch D57.08Neutral
- IndicatorValueSignal
- BB Upper885.45Neutral
- BB Middle799.61Neutral
- BB Lower713.76Neutral
- ATR68.05Low Volatility
- IndicatorValueSignal
- MFI68.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6803.44Bullish
- SMA 12861.15Bearish
- SMA 24893.07Bearish
- EMA 6822.56Bullish
- EMA 12839.45Bearish
- EMA 24804.75Bullish
- DEMA 6805.58Bullish
- DEMA 12831.06Bullish
- DEMA 24941.33Bearish
- TEMA 6815.64Bullish
- TEMA 12779.83Bullish
- TEMA 24N/AN/A
- MACD226.82Bearish
- ADX34.39Strong Trend
- IndicatorValueSignal
- RSI54.87Neutral
- CCI52.77Neutral
- ROC 2550.72Bullish
- ROC 50296.62Bullish
- Stoch K52.36Neutral
- Stoch D71.01Neutral
- IndicatorValueSignal
- BB Upper1135.40Neutral
- BB Middle911.69Neutral
- BB Lower687.98Neutral
- ATR159.77Low Volatility
- IndicatorValueSignal
- MFI46.74Neutral